A Closer Look at Amylyx Pharmaceuticals Inc (AMLX)’s Operating Margin

Amylyx Pharmaceuticals Inc [AMLX] stock prices are up 5.07% to $14.52 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AMLX shares have gain 9.09% over the last week, with a monthly amount glided 53.65%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Previously, Guggenheim started tracking the stock with Buy rating on June 24, 2025, and set its price target to $17. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $12 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Mizuho upgraded its rating to a Outperform but $7 remained the price target by the analyst firm on April 07, 2025. Robert W. Baird upgraded its rating to Outperform for this stock on November 18, 2024, and upped its price target to $11. In a note dated October 23, 2024, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $4.20 to $10.

The stock price of Amylyx Pharmaceuticals Inc [AMLX] has been fluctuating between $2.60 and $14.20 over the past year. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $14.52 at the most recent close of the market. An investor can expect a potential return of 20.52% based on the average AMLX price forecast.

Analyzing the AMLX fundamentals

The Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] reported sales of -0.25M for trailing twelve months, representing a surge of 100.00%. Gross Profit Margin for this corporation currently stands at 5.46% with Operating Profit Margin at 791.06%, Pretax Profit Margin comes in at 755.96%, and Net Profit Margin reading is 753.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.96, Equity is -1.03 and Total Capital is -1.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.94 points at the first support level, and at 13.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.85, and for the 2nd resistance point, it is at 15.18.

Ratios To Look Out For

It’s worth pointing out that Amylyx Pharmaceuticals Inc [NASDAQ:AMLX]’s Current Ratio is 8.72. Further, the Quick Ratio stands at 8.72, while the Cash Ratio is 2.71.

Transactions by insiders

Recent insider trading involved Mazzariello Gina, Chief Legal Officer, that happened on Aug 13 ’25 when 15000.0 shares were sold. Chief Legal Officer, Mazzariello Gina completed a deal on Aug 12 ’25 to sell 15000.0 shares. Meanwhile, Officer GINA MAZZARIELLO bought 30000.0 shares on Aug 12 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.